NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $39.04 +0.13 (+0.33%) (As of 02:52 PM ET) Add Compare Share Share Today's Range$38.45▼$39.7350-Day Range$30.92▼$38.9152-Week Range$18.61▼$39.73Volume152,164 shsAverage Volume373,543 shsMarket Capitalization$2.22 billionP/E Ratio16.90Dividend YieldN/APrice Target$41.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Harmony Biosciences alerts: Email Address Harmony Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside5.8% Upside$41.33 Price TargetShort InterestBearish28.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 16 Articles This WeekInsider TradingN/AProj. Earnings Growth59.36%From $2.19 to $3.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 starsMedical Sector430th out of 927 stocksPharmaceutical Preparations Industry202nd out of 425 stocks 1.3 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 7 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.55% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 23.5, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 0.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 3.9 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search Interest1 people have searched for HRMY on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 59.36% in the coming year, from $2.19 to $3.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 16.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 16.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.16.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.75. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market JARBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a shooter's exact location.Don't miss out. Get the full details on this AI bargain. About Harmony Biosciences Stock (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesSeptember 16 at 2:01 AM | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for Harmony Biosciences (NASDAQ:HRMY)September 12, 2024 | americanbankingnews.comHarmony Biosciences (NASDAQ:HRMY) Coverage Initiated at UBS GroupSeptember 16, 2024 | The Freeport Society (Ad)Elon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.September 11, 2024 | benzinga.comHarmony Biosciences (NASDAQ:HRMY) Stock Quotes, Forecast and News SummarySeptember 10, 2024 | benzinga.comUnveiling 6 Analyst Insights On Harmony BiosciencesSeptember 10, 2024 | msn.comUBS Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy RecommendationSeptember 10, 2024 | benzinga.comNeurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst SaysSeptember 9, 2024 | stocknews.comUndervalued Biotech Stocks Ready for a BreakoutSeptember 16, 2024 | The Freeport Society (Ad)Elon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.August 25, 2024 | msn.comHarmony Biosciences Set to Engage at Key Investor ConferencesAugust 21, 2024 | prnewswire.comHARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESAugust 19, 2024 | seekingalpha.comHarmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline PotentialAugust 15, 2024 | seekingalpha.comHarmony Biosciences: Advancing An Expanded PipelineAugust 7, 2024 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | markets.businessinsider.comHarmony Biosciences Holdings Sell Rating Affirmed Amid Slowing Patient Growth and Unchanged Revenue GuidanceAugust 6, 2024 | msn.comUpdate: OLPX, HRMY, GLDD and III, August 6August 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Harmony Biosciences on Strong Earnings and Promising Drug Formulation ProspectsAugust 6, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call TranscriptSee More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/16/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$41.33 High Stock Price Target$56.00 Low Stock Price Target$27.00 Potential Upside/Downside+5.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.31 Trailing P/E Ratio16.91 Forward P/E Ratio17.84 P/E Growth0.75Net Income$128.85 million Net Margins17.53% Pretax Margin25.15% Return on Equity22.97% Return on Assets13.96% Debt Debt-to-Equity Ratio0.32 Current Ratio3.13 Quick Ratio3.09 Sales & Book Value Annual Sales$656.11 million Price / Sales3.38 Cash Flow$2.73 per share Price / Cash Flow14.29 Book Value$7.97 per share Price / Book4.90Miscellaneous Outstanding Shares56,792,000Free Float39,300,000Market Cap$2.22 billion OptionableOptionable Beta0.73 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 56)Founder & Non-Executive Chairman Comp: $185.67kDr. Jeffrey M. Dayno M.D. (Age 67)President, CEO & Director Comp: $1.26MMr. Sandip S. Kapadia CPA (Age 54)M.B.A., Executive VP, Chief Administrative Officer & CFO Comp: $813.52kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGeneral Counsel & Corporate SecretaryMs. Tricia GloverChief Compliance OfficerMs. Audrey Murphy SPHRVice Presidet of Human ResourcesMs. Cate McCanlessHead of Corporate Affairs & Public PolicyMs. Kelli WrightSenior Manager of Patient Advocacy & Harmony BiosciencesMore ExecutivesKey CompetitorsAimmune TherapeuticsNASDAQ:AIMTRa PharmaceuticalsNASDAQ:RARXTaro Pharmaceutical IndustriesNYSE:TAROXencorNASDAQ:XNCROPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsCim LLCBought 1,705 shares on 9/6/2024Ownership: 0.024%Algert Global LLCSold 25,000 shares on 8/16/2024Ownership: 0.181%Quarry LPBought 2,052 shares on 8/16/2024Ownership: 0.004%AXA S.A.Sold 856 shares on 8/15/2024Ownership: 0.065%The Manufacturers Life Insurance Company Sold 477 shares on 8/15/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $32.30 at the beginning of 2024. Since then, HRMY stock has increased by 20.9% and is now trading at $39.06. View the best growth stocks for 2024 here. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its earnings results on Tuesday, August, 6th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.24. The company's revenue for the quarter was up 28.8% on a year-over-year basis. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional investors include Pacer Advisors Inc. (4.42%), Dimensional Fund Advisors LP (1.68%), American Century Companies Inc. (1.20%) and Renaissance Technologies LLC (1.05%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR) and Commercial Metals (CMC). This page (NASDAQ:HRMY) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.